Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development
about
Chemical Variations on the p53 Reactivation ThemeModulation of Protein-Protein Interactions for the Development of Novel TherapeuticsOsteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate TherapiesFocusing on shared subpockets - new developments in fragment-based drug discoveryTargeting the Checkpoint to Kill Cancer CellsMolecular targeted approaches to cancer therapy and prevention using chalconesTransient Protein States in Designing Inhibitors of the MDM2-p53 InteractionDiscovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical DevelopmentThe role of p53 in cancer drug resistance and targeted chemotherapyP53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic LeukemiaA p53 drug response signature identifies prognostic genes in high-risk neuroblastomaThe pharmacodynamics of the p53-Mdm2 targeting drug Nutlin: the role of gene-switching noiseEnergetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 InteractionFBXO44-Mediated Degradation of RGS2 Protein Uniquely Depends on a Cullin 4B/DDB1 Complex.Open access to high-content clonogenic analysis.P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis.Discovery of 4-((3'R,4'S,5'R)-6″-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2″-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3″-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine DoubleWIP1 phosphatase as pharmacological target in cancer therapy.MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity.Organocatalytic, diastereo- and enantioselective synthesis of nonsymmetric cis-stilbene diamines: a platform for the preparation of single-enantiomer cis-imidazolines for protein-protein inhibition.Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2-p53 Interaction.Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonismSmall-molecule inhibitors of protein-protein interactions: progressing toward the reality.Induced protein degradation: an emerging drug discovery paradigm.SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regressionRetroperitoneal liposarcoma: current insights in diagnosis and treatmentSmall-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.The SIX1-EYA transcriptional complex as a therapeutic target in cancer.Wild type p53 reactivation: from lab bench to clinic.Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach.Small-molecule inhibitors that target protein-protein interactions in the RAD51 family of recombinasesSmall-molecule MDM2-p53 inhibitors: recent advances.Alternative modulation of protein-protein interactions by small moleculesHow To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma.Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097Potential Therapeutic Targets in Uterine Sarcomas.Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cellsInhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA
P2860
Q26749008-9DC94B6A-5267-415A-878E-3EDB8880EF4CQ26775356-9E9CE834-A8F4-4520-B9E5-1C45F4CC8970Q26782646-797A7C15-11D2-4982-BB09-BC7203ACA6F6Q26795719-79E1E4F2-4168-4F48-A821-6E9B2D52AC1DQ26795781-715B6166-78A0-4D51-B2A9-5C097F0A81EAQ27021479-A73CBB75-D8F5-4110-A016-42E8E5E7B409Q27680560-B3EE4FA0-DFFD-432C-B8AD-B8DE78552C17Q27684218-98450706-4F90-4F54-8036-446F438EFE68Q28072553-B8C0D147-761B-4E10-B27C-305FA40032A7Q28078609-6A9E1115-AF84-4A93-8110-B73408066836Q28537647-A0EE80DA-D93A-4200-B748-DE5C284D0C4DQ28542661-37AAAE46-8EDA-4543-8EF0-407BAC428236Q28550874-FE3E1C8B-35B7-47CE-9D71-04F94997B0EBQ30176404-AC140C31-B211-4EB3-82E1-68CE71F392A3Q30487407-28EE90AF-EC04-4B31-8510-59EE8ECC0118Q33430602-85E975D6-EBB5-4BDF-9829-617830A3D0C6Q33572704-B82BAFB6-EFE8-4509-8104-99DE240F4EE7Q33720757-4342ECBE-BC91-430B-ABA3-2A04F900EE15Q33869257-AF7FF4F9-31E7-4A54-B2CF-327CDC5C9CA7Q33918015-15E7C0F7-DE7A-491A-BAE1-4665F441D323Q33998827-6DB2E3A8-90A1-489B-82DF-6925B4964AB1Q34063712-C873B318-F9F6-4B7B-AC9A-29B34B0E954CQ34079481-C70113A1-7A72-4B17-8BC9-85EE610AF77DQ34263719-7EE66D1F-25AE-4FEF-A6D0-FF228EF6DB2AQ34545841-853E18D7-5648-48D9-8E7C-E1D6481B0444Q34584722-99477797-B3A4-4F5B-8912-19B6C5A3CB0DQ35066363-D3D0BE20-B1DE-4D1B-B7A5-AD0525266413Q35087851-F557FC15-C147-494F-B0AE-B9D2497903E0Q35107900-90503E40-82AD-4F74-B731-88D47875FA49Q35146343-7C2C119A-6E08-4D96-B1CD-B93E6B557259Q35411745-8F18D830-47BD-4EBE-AB3C-573A751D237EQ35484644-6017B8C2-CB89-4715-8838-38CE36F27A15Q35617077-5DF3A436-212C-480B-BC8D-AE544A55861FQ35620999-8791708C-A653-4155-9DBD-13F2630F4957Q35871210-D6B22D54-9415-4016-84F4-E5B8ED22E8D5Q36040768-6BFD4FD2-6B26-4FD9-82E0-19073460D7F8Q36132787-056C9714-5A80-46B7-8302-3290128016ECQ36245677-8014DDE2-72F4-4576-BC47-F59A61941F60Q36485161-A9BF9DDC-9696-4E8A-80C0-983134D65945Q36545083-1AF5220F-E3F1-482A-BFF4-17F889AB8781
P2860
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development
@ast
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development
@en
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development
@nl
type
label
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development
@ast
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development
@en
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development
@nl
prefLabel
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development
@ast
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development
@en
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development
@nl
P2093
P3181
P356
P1476
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development
@en
P2093
Bradford Graves
Brian Higgins
Cheryl Janson
Christian Tovar
David Bartkovitz
Frank Podlaski
Jin-Jun Liu
Jing Zhang
Kathryn Packman
Kelli Glenn
P304
P3181
P356
10.1021/JM400487C
P407
P577
2013-07-25T00:00:00Z